Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing
GBI Research's new report, "Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing" provides an in-depth analysis of the trends, issues and challenges in the pharmaceutical market in Brazil. The report analyzes the overall pharmaceutical and outsourcing market structure of the country. The report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Brazilian pharmaceutical market. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The Brazilian pharmaceutical market is one of the top emerging markets globally. In terms of revenue it is the seventh largest market in the world and the largest in Latin America. Since the introduction of the new Patent Law in 1997, many foreign pharmaceutical companies have entered the Brazilian market. However, due to the lack of government support in the country, these companies (MNCs) have mostly partnered with local players for the expansion of their services.
GBI Research analysis shows that generics have achieved higher growth in the market due to legal and regulatory support. The generics accounted for 20.6% of the market share in 2011 and are expected to grow in future. Both private and public sectors are playing a role in the healthcare infrastructure of the country. The availability of reasonably priced raw materials and good access to the patient pool, well-equipped facilities, high-quality staff and infrastructure are the major attractions for foreign players.
The Brazilian pharmaceutical market grew at a CAGR (Compound Annual Growth Rate) of 9% between 2004 and 2010. The economic growth of the country was above the world average and inflation was low compared to Argentina and Paraguay. In accordance with the Brazilian Ministry of Health, the private healthcare sector contributes approximately 2% of Brazil's GDP.
According to GBI Research's analysis, the Brazilian pharmaceutical market poses a number of challenges due to its diverse nature, which creates difficulties in terms of understanding the characteristics of sub-regions. The major challenge for foreign players planning to enter the market is the legal framework of the country. This forces the companies into partnering with local companies, resulting in profit and control sharing. The legal and regulatory framework for patents is limited, leading to a lack of protection for intellectual property rights. This tends to result in difficulties for companies spending on R&D.
The overall pharmaceutical, biotech and outsourcing market structure in Brazil
A market characterization of the Brazilian pharmaceutical market, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channels and intellectual property rights.
Brazilian CRO market growth
Analysis of the leading segments within the Brazilian pharmaceutical industry
Market drivers and restraints that have a significant impact on the market.
Competitive benchmarking of the leading companies in the pharmaceutical and CRO markets.
Key M&A activities and strategic partnership deals that have taken place between 2004 and mid-2011.
Reasons to buy
Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
Develop a tailored country strategy through the understanding of key drivers and barriers of each country's pharmaceutical market.
Develop key strategic initiatives by understanding the key focus areas of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
3 Emerging Pharmaceutical Market: Brazil - Industry Characterstics 11
3.1 Market Size and Market Forecast 11
3.2 Market Share by Therapy Area 12
3.3 Branded versus Generic Market Share 13
3.4 R&D Expenditure Innovations 14
3.4.1 Increased Screening Rates during R&D 14
3.5 Top Pharmaceutical Companies in Brazil 15
3.5.1 Domestic Players 15
3.5.2 Foreign Players 20
3.6 Drivers and Challenges 24
3.6.1 Drivers 24
3.6.2 Barriers 25
3.7 Healthcare Delivery System 26
3.7.1 Brazil Healthcare Delivery Opportunities 26
3.7.2 Brazil Healthcare Delivery Challenges 27
3.8 PESTLE Analysis 29
3.8.1 Political factors 29
3.8.2 Economic factors 29
3.8.3 Social factors 29
3.8.4 Technological factors 30
3.8.5 Legal factors 30
3.8.6 Environmental factors 30
4 Emerging Pharmaceutical Market: Brazil - Macroeconomic Environment 31
4.1 Demographic Analysis 31
4.1.1 Population Size, Growth, and Structure 31
4.1.2 Disease Overview in Brazil 34
4.2 GDP 39
4.3 Per Capita Income 41
4.3.1 Context 41
4.3.2 Analytical Framework 41
4.4 Healthcare Expenditure 42
4.4.1 Context 42
4.4.2 Analytical Framework 43
4.5 Healthcare Infrastructure 44
4.5.1 Analytical Framework 45
5 Emerging Pharmaceutical Market: Brazil -Healthcare Regulation 47
5.1 Pharmaceutical Regulation in Brazil 47
5.2 Drug Approval Process 47
5.3 Drug Registration Process 48
5.4 Patents and Generics (IPR) 49
5.5 Health Insurance Coverage 50
5.6 Clinical Trials 50
5.6.1 Context 50
5.6.2 Analytical Framework 51
5.7 Pricing and Reimbursement 51
5.7.1 Private Insurance 52
5.7.2 Hospotels 55
5.7.3 Cosmetic Travel 55
5.8 Regulatory Bodies 56
5.8.1 Ministry of Health (MOH) 56
5.8.2 Unified Health System (UHS also called as SUS in Brazil) 57
6 Emerging Pharmaceutical Market: Brazil - Industry Trends 58
6.1 Mergers and Acquisitions 58
6.1.1 M&A Deals by Year 58
6.1.2 Deal by Value 59
6.1.3 Recent M&A Deals 60
6.1.4 Top Five M&As 60
6.2 Co-development Deals 61
6.2.1 Deals by Year 61
6.2.2 Deal by Value 62
6.2.3 Recent Co-development Deals 62
6.2.4 Top Co-development Deals 63
6.3 Licensing Agreements 64
6.3.1 Deals by Year 64
6.3.2 Deals by Value 65
6.3.3 Recent Licensing Agreements 65
6.3.4 Top Licensing Agreements 66
7 Emerging Pharmaceutical Market: Brazil - CRO Industry 67
7.1 Contract Research Organization (CRO) Market Size and Growth 67
7.1.1 PPD 67
7.1.2 PRA International 68
7.1.3 ICON 69
7.1.4 Theorem Clinical Research 70
7.1.5 PAREXEL 71
7.1.6 Intrials 72
7.1.7 Eurotrials 73
7.1.8 PGS Medical/Statistics 74
7.1.9 INC Research 75
7.1.10 Chiltern 76
7.1.11 Covance 77
7.1.12 Quintiles 78
8 Emerging Pharmaceutical Market: Brazil - Appendix 79
Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing published by GBI Research in July 1, 2012. This report consists of Pages: 81 and the price starts from US $ 3500.
The contents of this page may be different from the latest version. Please contact us for details.